domenica, 9 agosto 2026

Notizie AIOM – anno XVII n. 735

3 Settembre 2019

FDA Delays Decision on Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

Aug 30, 2019 - The FDA has extended the review period for a supplemental biologics license application (sBLA) for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell ...
Leggi tutto

3 Settembre 2019

FDA Recommendation on Duodenoscopes With Disposable Components

Aug 30, 2019 - The U.S. Food and Drug Administration (FDA) has recommended that duodenoscope manufacturers and health-care facilities transition to different types of duodenoscopes that may pose less risk to patient safety. Specifically, because of challenges with cleaning ...
Leggi tutto

3 Settembre 2019

Atezolizumab Plus Nab-Paclitaxel Approved in Europe for Frontline TNBC

Aug 29, 2019 - The European Commission (EC) has approved the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC), according ...
Leggi tutto

3 Settembre 2019

29 agosto 2019 – Nota Informativa Importante su Mitomycin C 40 mg

3 Settembre 2019

Global public meeting on draft ICH guideline on clinical trials

Aug 30, 2019 - The global guidance for the conduct of clinical trials is currently undergoing a major revision. As part of the worldwide consultation process, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is ...
Leggi tutto

29 agosto 2019 – Rilascio online nuovo sistema di rimborso – MEA finanziari

Elotuzumab Triplet Approved in Europe for Multiple Myeloma

Aug 27, 2019 - The European Commission has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and ...
Leggi tutto

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non–small-cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. We conducted a randomized study to determine the optimal maintenance ...
Leggi tutto

26 agosto 2019 – Epatite C: aggiornamento del 26/08/2019 sui pazienti arruolati

Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study

The study aimed to investigate if assisted reproductive technology (ART) treatment or a diagnosis of infertility were associated with the risk of ovarian cancer or borderline ovarian tumors (BOT) in parous women. In a population-based register study of 1,340,097 women with ...
Leggi tutto